![]() |
Name |
Tremulenolide D
|
Molecular Formula | C15H22O2 | |
IUPAC Name* |
(6R,6aR,9aS)-6,8,8-trimethyl-1,4,5,6,6a,7,9,9a-octahydroazuleno[4,5-c]furan-3-one
|
|
SMILES |
C[C@@H]1CCC2=C(COC2=O)[C@@H]3[C@@H]1CC(C3)(C)C
|
|
InChI |
InChI=1S/C15H22O2/c1-9-4-5-10-13(8-17-14(10)16)12-7-15(2,3)6-11(9)12/h9,11-12H,4-8H2,1-3H3/t9-,11-,12+/m1/s1
|
|
InChIKey |
PNSDVYLOAYHPKJ-JLLWLGSASA-N
|
|
Synonyms |
Tremulenolide D
|
|
CAS | NA | |
PubChem CID | 139586167 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 234.33 | ALogp: | 3.5 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 3 |
Heavy Atoms: | 17 | QED Weighted: | 0.59 |
Caco-2 Permeability: | -4.616 | MDCK Permeability: | 0.00002090 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.014 |
Blood-Brain-Barrier Penetration (BBB): | 0.35 | Plasma Protein Binding (PPB): | 97.13% |
Volume Distribution (VD): | 3.203 | Fu: | 2.94% |
CYP1A2-inhibitor: | 0.166 | CYP1A2-substrate: | 0.87 |
CYP2C19-inhibitor: | 0.101 | CYP2C19-substrate: | 0.774 |
CYP2C9-inhibitor: | 0.304 | CYP2C9-substrate: | 0.945 |
CYP2D6-inhibitor: | 0.074 | CYP2D6-substrate: | 0.856 |
CYP3A4-inhibitor: | 0.064 | CYP3A4-substrate: | 0.238 |
Clearance (CL): | 10.406 | Half-life (T1/2): | 0.363 |
hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.388 |
Drug-inuced Liver Injury (DILI): | 0.178 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.817 | Maximum Recommended Daily Dose: | 0.607 |
Skin Sensitization: | 0.301 | Carcinogencity: | 0.301 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.024 |
Respiratory Toxicity: | 0.917 |